000020 — Dongwha Pharm Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩235bn
- KR₩231bn
- KR₩361bn
- 62
- 64
- 52
- 66
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 120,019 | 113,731 | 119,210 | 100,875 | 87,234 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 80,152 | 61,932 | 61,094 | 69,814 | 74,368 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 235,457 | 222,743 | 220,199 | 227,527 | 237,700 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 99,215 | 130,951 | 142,851 | 151,153 | 188,330 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 376,029 | 433,808 | 447,804 | 461,136 | 564,972 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 55,715 | 67,494 | 66,461 | 75,562 | 106,134 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 75,154 | 102,552 | 100,870 | 96,736 | 193,193 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 300,875 | 331,256 | 346,935 | 364,400 | 371,780 |
Total Liabilities & Shareholders' Equity | 376,029 | 433,808 | 447,804 | 461,136 | 564,972 |
Total Common Shares Outstanding |